Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mindset Pharma (MSET) announces its inclusion in the AdvisorShares Psychedelics ETF
  • PSIL is an actively managed exchange-traded product that invests in the emerging psychedelic drugs sector
  • The  AdvisorShares Psychedelics ETF is traded on the NYSE Arca under the ticker symbol PSIL
  • Mindset Pharma is a drug discovery and development company focused on creating next-generation psychedelic medicines
  • Mindset Pharma (MSET) opened trading at C$0.80 per share

Mindset Pharma (MSET) has announced its inclusion in the NYSE-traded AdvisorShares Psychedelics ETF.

The  AdvisorShares Psychedelics ETF is traded on the NYSE Arca under the ticker symbol PSIL.

PSIL is an actively managed exchange-traded product that invests in the emerging psychedelic drugs sector. The PSIL offers exposure to biotechnology, pharmaceutical and life sciences companies deriving the majority of their net revenue or devoting the majority of their assets to psychedelic drugs, and only holds companies that they see as leading the way in this industry.

James Lanthier, Chief Executive Officer of Mindset commented on the news.

“Mindset’s inclusion in the actively-managed PSIL is another positive step in building awareness and education for the exciting developments at Mindset, as well as the psychedelics industry as a whole. We are thrilled to be considered a leader in the space and appreciate the support from the capital markets as we progress our differentiated pipeline of next generation psychedelic-inspired drug candidates towards the clinic.”

Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders.

Mindset Pharma (MSET) opened trading at C$0.80 per share.

More From The Market Herald
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.